Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
Satoshi NakataJunko MuraiMasayasu OkadaHaruhiko TakahashiTyler H FindlayKristen MalebrancheAkhila ParthasarathySatoshi MiyashitaRamil GabdulkhaevIlan BenkimounSabine DruillennecSara ChabiEleanor HawkinsHiroaki MiyaharaKensuke TateishiShinji YamashitaShiori YamadaTaiki SaitoJotaro OnJun WatanabeYoshihiro TsukamotoJunichi YoshimuraMakoto OishiToshimichi NakanoMasaru ImamuraChihaya ImaiTetsuya YamamotoHideo TakeshimaAtsuo T SasakiFausto J RodriguezSumihito NobusawaPascale VarletCelio PouponnotSatoru OsukaYves PommierAkiyoshi KakitaYukihiko FujiiEric H RaabeCharles G EberhartManabu NatsumedaPublished in: Neuro-oncology (2022)
High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.